An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3429-3434

  Stathopoulos, George P ^a,c   Papadopoulos, Nicos G ^b   Stephanopoulou, Anastasia ^a   Dontas, Ismene ^a   Kotsarelis, Despina ^a   Karayannacos, Panayiotis E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Anticancer Institute   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Anthracyclins; Cardiotoxicity; Cholesterol; Doxoruhicin; Epirubicin; Lipids

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CHOLESTEROL; DOXORUBICIN; EPIRUBICIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PROTEIN; TRIACYLGLYCEROL;

ABDOMINAL WALL MUSCULATURE; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GREAT BLOOD VESSEL; HEART MUSCLE; LIPID BLOOD LEVEL; LIVER; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; EPIRUBICIN; FEMALE; LIPIDS; LIPOPROTEINS, HDL; MALE; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 0030514284     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bonadonna G, Monfardini S, Delena M, Fossati-Bellanti F: Clinical evaluation of adriamycin, a new antitumor antibiotic. Br Med J 3: 503-507, 1969.
2. Blum RH, Carter SK: Adriamycin: A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249-259, 1984.
3. Von Hoff DD, Rozencweig M, Piccart M: The cardiotoxicity of anticancer agents. Semin Oncol 9: 23-33, 1982.
4. 2. Evidence for enhanced toxicity with multiagent chemotherapy. Am J Hematol 36: 217-218, 1991.
5. Goorin AM, Borow KM, Goldman A et al: Congestive heart failure due to adriamycin cardiotoxicity. Its natural history in children. Cancer 4: 2810-2816, 1981.
6. Weiss RB, Sarosy G, Glagett-Carr K, Russo M, Leyland-Jones B: Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 18: 185-197, 1986.
7. Herman EH, Ferrans VJ. Pathophysiology of anthracycline cardiotoxicity. In: Cardiac toxicity after treatment for childhood cancer. (Bricker JT, Green MD, D' Angio GJ, eds). New York, Wiley-Liss, pp 25-34, 1993.
8. Bristow MR, Sageman SW, Scott RH et al: Acute and chronic effects of doxorubicin in the dog. The cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 2: 487-515, 1980.
9. Robert J, Vrignaud P, Ngven-Ngoc T, et al: Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69: 633-640, 1985.
10. Armitage P, Berry G: Multiple measurements In: Statistical Methods in Medical research. 2nd ed. Oxford, Blackwell Scientific Publications, pp 296-357, 1991.
11. Billingham ME, Mason J, Bristow M, Daniels J: Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 62: 865-872, 1978.
12. LeBot MA, Begue JM, Kernaleguen D et al: Different cytotoxicity and metabolism of doxorubicin. daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes. Biochem Pharmacol 37: 3877-3887, 1988.
13. Bigotte L, Olsson Y: Distribution and toxic effect of intravenously injected epirubicin on the central nervous system of the mouse. Brain 112: 457-469, 1989.
14. Doroshow JH: Effect of anthracyclin antibiotics on oxygen radical formation in rat heart. Cancer Res 43: 460-472, 1983.
15. Plosker GL, Faulds D: Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45: 788-856, 1993.
16. Genest JJ, Munley MS, Me Namara JR et al: Prevalence of familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 85:2025-2033, 1992.
17. Scriver CR, Beaudet AL, Sly WS, et al: Eds Lipoprotein and lipid metabolism disorders, in: The Metabolic Base of Inherited Disease. 6th ed. New York, McGraw-Hill, pp 1129-1302, 1989.
18. Assman G, Ed. Lipid metabolism disorders and coronary heart disease, pp 165-191, 1993.
19. Tritton TR, Murphee SA, Sartorelli AC: Adriamycin: A proposal on the specificity of drug action. Biochem Biophys Res Commun 84: 802-808, 1978.
20. Rothblatt GH, Phillips MC: Cholesterol efflux from arterial wall cells. Curr Opin Lipidol 2: 288-294, 1991.
21. Lund-Katz S: Cell membrane structure and lipoprotein metabolism. Curr Op Lipidol 6: 146-152, 1995.
22. Stathopoulos GP, Stergiou GS, Perrea-Kostarelis DN, Dontas IA, Karamanos BG, Karayiannacos PE: Influence of 5-fluorouracil on serum lipids. Acta Oncol 34: 253-256, 1995.